Adams Respiratory Therapeutics, Inc., a specialty pharmaceutical company, focuses on late-stage development, commercialization, and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. The company markets 10 products, including Mucinex SE, Mucinex DM, Mucinex D, Humibid SE, 2 Delsym products, and 4 products in children's Mucinex line. It is also developing additional products using its extended-release guaifenesin-based technology and initiated a Phase IIb clinical trial for the U.S. clinical development of erdosteine, a new mucolytic in March 2006. It sells its products to drug wholesalers, retail drug stores, mass merchandisers, and...